Domique Figarella-Branger

25PUBLICATIONS
128CO-AUTHORS
Cancer diagnosisHaematological tumoursPredictive and prognostic markersMedical infection agents (incl. prions)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Aug 31, 2025
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors.

Pieter Wesseling, David Capper, Guido Reifenberger

|Nov 08, 2024
Phenotypic and epigenetic heterogeneity in FGFR2-fused glial and glioneuronal tumours.

Alice Métais, Volodia Dangouloff-Ros, Jeremy Garcia

|Oct 21, 2024
Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort.

Domique Figarella-Branger, Carole Colin, Karima Mokhtari

|Oct 02, 2024
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Salah Eddine O Kacimi, Caroline Dehais, Loïc Feuvret

|Aug 02, 2024
Descriptive epidemiology of 399 histologically confirmed newly diagnosed meningeal solitary fibrous tumours and haemangiopericytomas in France: 2006-2015.

Charles Champeaux Depond, Sonia Zouaoui, Amélie Darlix

|Jun 24, 2024
The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

Martin J van den Bent, Pim J French, Daniel Brat

Pageof 5

Frequent Collaborators

7 joint publications

Emeline Tabouret

3 joint publications

Martin van den Bent

3 joint publications

Ahmed Idbaïh

3 joint publications

Mehdi Touat